(将ARNI与ACEI进行前瞻性比较,以确定心力衰竭对全球死亡率和发病率的影响[范式-HF];NCT01035255) Footnotes ↵∗Drs. Myhre and Vaduganathan contributed equally to this work as co-first authors.The PARADIGM-HF trial was funded by ...
PARADIGM-HF试验结果公布后的5年多时间里,越来越多的数据进一步支持将脑啡肽酶抑制剂加入到传统的联合用药方案中。近日,J Am Coll Cardiol HF发表的一篇文章对沙库巴曲缬沙坦相关研究结果进行了回顾,并对其前景进行了展望,包括潜在的新适应证。 ...
PARADIGM-HF 研 究意义重大,有可能改变未来心力衰竭的治疗格局。 【关键词】 PARADIGM-HF 试验; 慢性射血分数降低心力衰竭; 血管紧张素受体和脑啡 肽酶双重抑制剂 PARADIGM-HF trial and its important clinical significance Liu Jinlai. Department of Cardiology, the Third Affiliated Hospital, SUN Yat-sun ...
西班牙巴塞罗那召开的欧洲心脏病学会(ESC)年会2014年8月30日正式公布了PARADIGMHF试验的结果,研究全文也在同日发表于《新英格兰医学杂志》.PARADIGM-HF试验全称prospec tive comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial,对比了血管紧张素受体和脑啡肽酶...
1.在PARADIGM-HF试验中,相比依那普利,沙库巴曲缬沙坦降低了慢性射血分数降低型心力衰竭(HFrEF)的发病率和死亡率; 2. 随后的一系列研究分析了PARADIGM-HF试验中沙库巴曲缬沙坦相比于依那普利的额外获益; 3.小型机制试验突出了沙库巴曲缬沙坦在缓解不良心肌重构中的有利作用; ...
诺华于4月2日宣布, PARADIGM-HF研究数据的最新分析显示,Entresto?(sacubitril/valsartan)可为射血分数降低的心衰(HFrEF)患者提供一致获益,即使患者临床稳定,并且不管背景治疗如何1,2。 PARADIGM-HF患者分析得出以下结果: 即使临床稳定(定义为无既往心衰住院史或具有久远的既往心衰住院史)的患者仍存在发生严重临床事件的...
(ARNI) reduced significantly primary endpoint(cardiovascular death or hospitalization for HF) [HR 0.80(95% CI 0.73-0.87), P0.001], cardiovascular death[HR 0.80(95% CI 0.71-0.89), P0.001], hospitalization for HF [HR 0.79(95% CI 0.71-0.89), P0.001], and death from any cause [HR 0.84(...
PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure? 摘要: E Kaplinsky - 《Journal of Geriatric Cardiology》 被引量: 13发表: 2015年 PARADIGM-HF研究结果解读 心力衰竭的药物治疗虽然取得很多进展,但慢性心力衰竭患者5年死亡率却与恶性肿瘤相似,寻求新的治疗手段已成必需....
effects both within and beyond the renin-angiotensin system, instead of the old-standby ACE inhibitor enalapril, will have fewer HF hospitalizations and die less often from cardiovascular causes, suggests a phase 3 trial that is huge both in size and its potential impact on clinical practice[1]...
The trial enrolled 8,442 patients with NYHA class II, III or IV HF and an ejection fraction ≤40% who were randomly assigned to receive LCZ696 400 mg daily orenalapril20 mg daily in addition to standard care. The mean age of the patients was 63.8 years, one-...